<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hemostasis and Coagulation Disorders</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\(', '\)']],
            displayMath: [['$$', '$$'], ['\[', '\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hematology-hemoglobinopathies-aplastic-anemia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 50%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 3 of 6</span> <!-- Update text -->
                    </div>
                    <a href="hematology-myeloid-malignancies.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Hemostasis</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: hemostasis-phases -->
                <section id="hemostasis-phases" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">THREE PHASES OF HEMOSTASIS</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Primary Hemostasis</h3>
                        <ul>
                            <li>goal is to rapidly stop bleeding</li>
                            <li>vessel injury results in collagen and subendothelial structure exposure and release of vasoconstrictors</li>
                            <li>blood flow is impeded and platelets come in contact with vessel wall</li>
                            <li>platelets adhere to collagen and are activated resulting in change of shape and release of ADP and thromboxane A2</li>
                            <li>these factors further recruit and aggregate more platelets resulting in formation of hemostatic plug</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_09_19_3f788f8fa9a6daaca993g-16-1.jpg" alt="Figure 2: Diagram of Primary Hemostasis showing platelet adhesion, activation, and aggregation to form a plug at the site of vessel injury." class="content-image">
                            <figcaption>Figure 2. Primary Hemostasis</figcaption>
                        </figure>

                        <h3 class="subsection-heading">Secondary Hemostasis</h3>
                        <ul>
                            <li>platelet plug formed through primary hemostasis is reinforced through process of secondary hemostasis and a stable plug is formed</li>
                            <li>secondary pathways involved in the activation of coagulation factors include
                                <ul>
                                    <li><strong>intrinsic</strong>
                                        <ul>
                                            <li>activated when vessel wall remains intact</li>
                                            <li>slow pathway</li>
                                        </ul>
                                    </li>
                                    <li><strong>extrinsic</strong>
                                        <ul>
                                            <li>activated when there is injury to vessel wall</li>
                                            <li>fast pathway</li>
                                        </ul>
                                    </li>
                                </ul>
                            </li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_09_19_3f788f8fa9a6daaca993g-17-1.jpg" alt="Figure 3: The coagulation cascade, illustrating the intrinsic, extrinsic, and common pathways leading to the formation of a fibrin clot." class="content-image">
                             <figcaption>Figure 3. The Coagulation Cascade</figcaption>
                        </figure>
                        <figure>
                             <img src="../assets/images/2025_09_19_3f788f8fa9a6daaca993g-17-2.jpg" alt="Figure 4: Diagram showing fibrin stabilization by Factor XIIIa and the process of fibrinolysis, where plasmin breaks down the fibrin clot." class="content-image">
                            <figcaption>Figure 4. Fibrin Stabilization and Fibrinolysis</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: hemostasis-phases -->

                <!-- START: tests-of-hemostasis -->
                <section id="tests-of-hemostasis" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">TESTS OF HEMOSTASIS</span>
                    </h2>
                    <div class="content-card">
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 8. Commonly Used Tests of Hemostasis</caption>
                                <thead>
                                    <tr><th>Type of hemostasis</th><th>Test</th><th>Reference Range</th><th>Purpose</th></tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Primary</td>
                                        <td>platelet count<br>bleeding time<br>platelet aggregation</td>
                                        <td>2-12 mins</td>
                                        <td>- to quantitate platelet number<br>- platelet function<br>- platelet function</td>
                                    </tr>
                                    <tr>
                                        <td>Secondary</td>
                                        <td>PTT - depends on lab<br>PT - depends on lab<br>TT - depends on lab<br>INR</td>
                                        <td>22-35 s<br>11-24 s<br>14-16 s<br>1 is normal</td>
                                        <td>- measures intrinsic pathway factors VIII, IX, XI, XII<br>- measures extrinsic pathway factor VIII in particular<br>- measures deficiency of fibrinogen inactivation of prothrombin<br>- permits determination of coagulation status independent of laboratory performing measurement</td>
                                    </tr>
                                    <tr><td>Fibrinolysis</td><td>euglobulin lysis time</td><td></td><td></td></tr>
                                    <tr>
                                        <td>Other</td>
                                        <td colspan="3">- fibrinogen<br>- fibrinogen degradation products (FDPs)<br>- specific factor assays<br>- tests of physiological inhibitors (antithrombins, protein S, protein C, hereditary resistance to APC)<br>- tests of pathologic inhibitors (e.g. lupus anticoagulant)</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                        <div class="table-container">
                             <table class="content-table">
                                <caption>Table 9. Signs and Symptoms of Disorders of Hemostasis</caption>
                                <thead>
                                    <tr><th></th><th>Primary (Platelet)</th><th>Secondary (Coagulation)</th></tr>
                                </thead>
                                <tbody>
                                    <tr><td>Surface Cuts</td><td>excessive, prolonged</td><td>normal/slightly prolonged</td></tr>
                                    <tr><td>Onset After Injury</td><td>immediate</td><td>delayed</td></tr>
                                    <tr><td>Typical Type and Site of Bleeding</td><td>superficial i.e. mucosal (nasal, gingival, GI tract, uterine), petechiae</td><td>deep i.e. into joints, muscles, GI tract, GU tract, excessive, post-traumatic</td></tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: tests-of-hemostasis -->

                <!-- START: primary-hemostasis-disorders -->
                <section id="primary-hemostasis-disorders" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">THROMBOCYTOPENIA AND OTHER DISORDERS OF PRIMARY HEMOSTASIS</span>
                    </h2>
                    <div class="content-card">
                        <p>inability to form an adequate platelet plug due to</p>
                        <ol>
                            <li>disorders of blood vessels</li>
                            <li>disorders of platelets
                                <ul>
                                    <li>abnormal function</li>
                                    <li>abnormal numbers</li>
                                </ul>
                            </li>
                        </ol>
                        <h3 class="subsection-heading">Classification</h3>
                        <h4>Vascular (Non-Thrombocytopenic Purpura)</h4>
                        <ul>
                            <li><strong>hereditary</strong>
                                <ul>
                                    <li>hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu)</li>
                                    <li>connective tissue disorders</li>
                                </ul>
                            </li>
                            <li><strong>acquired</strong>
                                <ul>
                                    <li>purpura simplex (easy bruising)</li>
                                    <li>senile purpura</li>
                                    <li>dysproteinemias</li>
                                    <li>Henoch-Schonlein Purpura</li>
                                    <li>scurvy</li>
                                    <li>Cushing's syndrome</li>
                                    <li>infections</li>
                                    <li>drugs</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Platelets</h4>
                        <ul>
                            <li><strong>dysfunction</strong>
                                <ul>
                                    <li>hereditary
                                        <ul><li>von Willebrand's disease, others (rare)</li></ul>
                                    </li>
                                    <li>acquired
                                        <ul>
                                            <li>drugs eg. ASA, EtOH, NSAIDs</li>
                                            <li>uremia</li>
                                            <li>myeloproliferative disorders</li>
                                            <li>dysproteinemias</li>
                                        </ul>
                                    </li>
                                </ul>
                            </li>
                             <li><strong>thrombocytopenia (usually acquired)</strong>
                                <ul>
                                    <li>decreased production
                                        <ul>
                                            <li>drugs, toxins</li>
                                            <li>radiation</li>
                                            <li>marrow infiltrate or failure</li>
                                        </ul>
                                    </li>
                                    <li>ineffective production
                                        <ul>
                                            <li>megaloblastic anemias</li>
                                            <li>myelodysplasia</li>
                                            <li>vitamin B12, folic acid or iron deficiency</li>
                                            <li>viral infections eg. varicella, mumps, HIV, EBV, CMV, parvo</li>
                                        </ul>
                                    </li>
                                    <li>increased destruction
                                        <ul>
                                            <li>drugs eg. quinidine, sulfas, thiazides, heparin</li>
                                            <li>ITP</li>
                                            <li>allo-antibodies</li>
                                            <li>HIV positive</li>
                                            <li>sepsis</li>
                                        </ul>
                                    </li>
                                     <li>increased consumption
                                        <ul>
                                            <li>DIC</li>
                                            <li>microangiopathies (TTP)</li>
                                        </ul>
                                    </li>
                                     <li>sequestration
                                        <ul><li>splenomegaly</li></ul>
                                    </li>
                                     <li>dilutional
                                        <ul><li>massive transfusion with stored blood</li></ul>
                                    </li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: primary-hemostasis-disorders -->

                <!-- START: itp -->
                <section id="itp" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">IDIOPATHIC (AUTOIMMUNE) THROMBOCYTOPENIC PURPURA (ITP)</span>
                    </h2>
                    <div class="content-card">
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 10. Idiopathic Thrombocytopenic Purpura</caption>
                                <thead>
                                    <tr><th>Features</th><th>Acute ITP</th><th>Chronic ITP</th></tr>
                                </thead>
                                <tbody>
                                    <tr><td>Peak Age</td><td>2-6 years</td><td>20-40 years</td></tr>
                                    <tr><td>Sex Predilection</td><td>none</td><td>F > M (3:1)</td></tr>
                                    <tr><td>History of Recent Infection</td><td>common</td><td>rare</td></tr>
                                    <tr><td>Onset of Bleed</td><td>abrupt</td><td>insidious</td></tr>
                                    <tr><td>Platelet Count</td><td>&lt;20 x 10<sup>9</sup>/L</td><td>30-80 x 10<sup>9</sup>/L</td></tr>
                                    <tr><td>Duration</td><td>usually weeks</td><td>months to years</td></tr>
                                    <tr><td>Spontaneous Remissions</td><td>80% or more</td><td>uncommon</td></tr>
                                </tbody>
                            </table>
                        </div>
                        <h3 class="subsection-heading">CHRONIC (ADULT-TYPE) ITP</h3>
                        <ul>
                            <li>most common cause of isolated thrombocytopenia</li>
                            <li>diagnosis of exclusion</li>
                        </ul>
                        <h4>Pathophysiology</h4>
                        <ul>
                            <li>IgG autoantibody</li>
                            <li>spleen
                                <ul>
                                    <li>site of antibody production and platelet destruction</li>
                                    <li>usually not palpable (enlarged in ~ 10%)</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Clinical Presentation</h4>
                        <ul>
                            <li>insidious onset</li>
                            <li>may be seen after mild viral illness or after immunization</li>
                            <li>mucosal or skin bleeding</li>
                            <li>petechiae and easy bruising</li>
                            <li>hematuria</li>
                            <li>melena</li>
                            <li>epistaxis</li>
                            <li>female with menorrhagia</li>
                        </ul>
                        <h4>Laboratory Results</h4>
                        <ul>
                            <li>peripheral blood film: decreased platelets, large platelets</li>
                            <li>bone marrow: plentiful megakaryocytes
                                <ul><li>critical test to rule out other causes of thrombocytopenia</li></ul>
                            </li>
                            <li>anti-platelet antibodies present in most</li>
                            <li>increased bleeding time</li>
                            <li>PT and PTT normal</li>
                        </ul>
                        <h4>Management</h4>
                        <ul>
                            <li>conservative if mild
                                <ul><li>platelet count > 30,000, no mucosal bleeding</li></ul>
                            </li>
                            <li>steroids: moderate dose, then taper (80% responsive)
                                <ul><li>platelet count < 20-30,000 or evidence of mucosal bleeding</li></ul>
                            </li>
                            <li>splenectomy if steroids fail</li>
                            <li>IV gamma globulin if steroids and splenectomy fail or if rapid response is required</li>
                            <li>other: immunosuppressives, platelets, plasma exchange, Danazol</li>
                        </ul>
                        <h4>Prognosis</h4>
                        <ul>
                            <li>fluctuating course</li>
                            <li>overall relatively benign, mortality 1-2%</li>
                            <li>major concern is cerebral hemorrhage at platelet counts &lt;5 x 10<sup>9</sup>/L</li>
                        </ul>
                    </div>
                </section>
                <!-- END: itp -->

                <!-- START: secondary-hemostasis-disorders -->
                <section id="secondary-hemostasis-disorders" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">DISORDERS OF SECONDARY HEMOSTASIS</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Classification</h3>
                        <h4>I. Hereditary</h4>
                        <ul>
                            <li>Factor VIII: Hemophilia A, von Willebrand's disease</li>
                            <li>Factor IX: Hemophilia B (Christmas Disease)</li>
                            <li>Factor XI</li>
                            <li>other factor deficiences are rare</li>
                        </ul>
                        <h4>II. Acquired</h4>
                        <ul>
                            <li>liver disease</li>
                            <li>DIC</li>
                            <li>vitamin K deficiency</li>
                            <li>circulating anti-coagulants (inhibitors)</li>
                            <li>other e.g. primary fibrinolysis</li>
                        </ul>

                        <h3 class="subsection-heading">HEREDITARY</h3>
                        <h4>I. Hemophilia A (factor VIII)</h4>
                        <ul>
                            <li>X-linked, 1/5,000 males</li>
                            <li>mild (> 5%), moderate (1-5%), severe (< 1%)</li>
                        </ul>
                        <h5>Clinical Presentation</h5>
                        <ul>
                            <li>hemarthroses, hematomas, GI and GU bleeding</li>
                            <li>bleeding in response to trauma (mild and moderate disease)
                                <ul><li>intracranial hemorrhage following head injury</li></ul>
                            </li>
                            <li>spontaneous bleeding (severe disease)</li>
                        </ul>
                        <h5>Laboratory Results</h5>
                        <ul>
                            <li>prolonged PTT, normal INR (PT)</li>
                            <li>decreased factor VIII (< 40% of normal)</li>
                            <li>vWF usually normal or increased</li>
                        </ul>
                        <h5>Management</h5>
                        <ul>
                            <li>minor but not trivial bleeding (eg. hemarthroses)
                                <ul><li>heat treated Factor VIII concentrate</li></ul>
                            </li>
                            <li>major potentially life-threatening bleeding (eg. multiple trauma)
                                <ul><li>heat treated Factor VIII concentrate</li></ul>
                            </li>
                            <li>prophylaxis (eg. multiple dental extractions, surgery)
                                <ul><li>heat treated Factor VIII concentrate</li></ul>
                            </li>
                            <li>DDAVP in mild or moderate hemophilia A</li>
                        </ul>

                        <h4>II. Von Willebrand's Disease</h4>
                        <ul>
                            <li>heterogeneous group of defects</li>
                            <li>usually autosomal dominant</li>
                            <li>qualitative or quantitative abnormality of vWF
                                <ul>
                                    <li>vWF needed for platelet adhesion and acts as carrier for factor VIII</li>
                                    <li>vWF exists as a series of multimers ranging in size</li>
                                    <li>the largest ones are most active in mediation of platelet adhesion</li>
                                    <li>both large and small complex with factor VIII</li>
                                </ul>
                            </li>
                            <li>both primary and secondary hemostasis affected</li>
                            <li>usually mild to moderate in severity</li>
                        </ul>
                        <h5>Classification</h5>
                        <ul>
                            <li>type I: decreased vWF in platelets and plasma (will see prolonged bleeding time, decreased factor VIII)</li>
                            <li>type IIA: decreased large and intermediate sized multimers in plasma and platelets (will see prolonged bleeding time, normal levels of factor VIII)</li>
                            <li>type IIB: largest multimers are missing from plasma but not from platelets</li>
                        </ul>
                        <h5>Clinical Presentation</h5>
                        <ul>
                            <li><strong>mild</strong>
                                <ul><li>asymptomatic</li><li>mucosal and cutaneous bleeding, easy bruising, epistaxis, menorrhagia, gingival bleeding</li></ul>
                            </li>
                            <li><strong>moderate to severe</strong>
                                <ul><li>as above but worse, occasionally soft-tissue hematomas, petechiae (rare), GI bleeding, hemarthroses</li></ul>
                            </li>
                        </ul>
                        <h5>Course</h5>
                        <p>may fluctuate, often improves during pregnancy and with age</p>
                        <h5>Laboratory Results</h5>
                        <ul>
                            <li>prolonged bleeding time and PTT</li>
                            <li>decreased factor VIII (5-50%)</li>
                            <li>normal platelet count (except in Type IIB)</li>
                            <li>decreased ristocetin cofactor activity</li>
                            <li>analysis of multimers</li>
                        </ul>
                        <h5>Management</h5>
                        <ul>
                            <li>DDAVP is treatment of choice except in Type IIB
                                <ul>
                                    <li>causes release of vWF and plasminogen activator from endothelial cells</li>
                                    <li>in type IIB, the appearance of the large multimers in the circulation can cause thrombocytopenia</li>
                                </ul>
                            </li>
                            <li>Hemate P in selected cases</li>
                            <li>conjugated estrogens</li>
                        </ul>

                        <h4>III. Factor IX Deficiency</h4>
                        <ul>
                            <li>Christmas disease, Hemophilia B</li>
                            <li>X-linked recessive, 1/30,000 males</li>
                            <li>clinical and laboratory features identical to Hemophilia A</li>
                            <li>main treatment is Factor IX concentrate</li>
                        </ul>

                        <h4>IV. Factor XI Deficiency (Rosenthal syndrome)</h4>
                        <ul>
                            <li>autosomal recessive inheritance</li>
                            <li>usually mild, often diagnosed in adulthood</li>
                            <li>treatment: fresh frozen plasma</li>
                        </ul>
                        
                        <h3 class="subsection-heading">ACQUIRED</h3>
                        <h4>I. Liver Disease</h4>
                        <ul>
                            <li>deficient synthesis of all factors except VIII</li>
                            <li>aberrant synthesis: fibrinogen</li>
                            <li>deficient clearance of hemostatic "debris" and fibrinolytic activators</li>
                            <li>accelerated destruction due to dysfibrinogenemias: increased fibrinolysis, DIC</li>
                            <li>thrombocytopenia: hypersplenism, folate deficiency, EtOH intoxication, DIC</li>
                            <li>platelet dysfunction: EtOH abuse</li>
                            <li>miscellaneous: inhibition of secondary hemostasis by FDPs</li>
                            <li>peripheral blood smear: target cells</li>
                            <li><strong>diagnosis</strong>
                                <ul>
                                    <li>factor V because it has the shortest half-life</li>
                                    <li>elevated INR (PT), PTT and bleeding time</li>
                                </ul>
                            </li>
                            <li><strong>treatment:</strong> fresh frozen plasma, platelets</li>
                        </ul>
                        
                        <h4>II. Vitamin K Deficiency</h4>
                        <h5>Etiology</h5>
                        <ul>
                            <li>poor diet (especially in alcoholics)</li>
                            <li>biliary obstruction</li>
                            <li>chronic liver disease</li>
                            <li>malabsorption e.g. celiac disease</li>
                            <li>drugs
                                <ul>
                                    <li>oral anticoagulants produce inhibition of factors II, VII, IX, X, Protein C & S</li>
                                    <li>antibiotics eradicating gut flora which is 50% of vitamin K supply</li>
                                </ul>
                            </li>
                            <li>hemorrhagic disease of newborn</li>
                        </ul>
                        <h5>Diagnosis</h5>
                        <ul>
                            <li>INR (PT) is elevated out of proportion to the elevation of the PTT</li>
                            <li>decreased factors II, VII, IX and X (because vitamin K-dependent)</li>
                        </ul>
                        <h5>Management</h5>
                        <ul>
                            <li>vitamin K 10-20 mg SC (not IM)</li>
                            <li>Note: PT should improve within 24 hours, if not search for other causes</li>
                        </ul>

                        <h4>III. Disseminated Intravascular Coagulation (DIC)</h4>
                        <p>massive uncontrolled intravascular coagulation resulting in depletion of platelets, coagulation factors and fibrinogen not a primary disorder but a syndrome that complicates a number of other conditions</p>
                        <h5>Clinical Conditions Associated with DIC</h5>
                        <ul>
                            <li><strong>activation of procoagulant activity</strong>
                                <ul>
                                    <li>anti-phospholipid antibody</li>
                                    <li>intravascular hemolysis (incompatible blood, malaria)</li>
                                    <li>tissue factor</li>
                                    <li>tissue injury (obstetric catastrophes, leukemia, tumours, liver disease, trauma, burns)</li>
                                    <li>snakebite</li>
                                    <li>fat embolism</li>
                                    <li>heat stroke</li>
                                </ul>
                            </li>
                            <li><strong>endothelial injury</strong>
                                <ul>
                                    <li>infections</li>
                                    <li>vasculitis</li>
                                    <li>metastatic disease (adenocarcinoma)</li>
                                    <li>aortic aneurysm</li>
                                    <li>giant hemangioma</li>
                                </ul>
                            </li>
                            <li><strong>reticuloendothelial injury</strong>
                                <ul>
                                    <li>liver disease</li>
                                    <li>splenectomy</li>
                                </ul>
                            </li>
                            <li><strong>vascular stasis</strong>
                                <ul>
                                    <li>hypotension</li>
                                    <li>hypovolemia</li>
                                    <li>pulmonary embolus</li>
                                </ul>
                            </li>
                             <li><strong>other</strong>
                                <ul>
                                    <li>acute hypoxia/acidosis</li>
                                    <li>extracorporeal circulation</li>
                                </ul>
                            </li>
                        </ul>
                        <h5>Signs of Microvascular Thrombosis (Early DIC)</h5>
                        <ul>
                            <li><strong>neurological:</strong> multifocal, delirium, coma, seizures</li>
                            <li><strong>skin:</strong> focal ischemia, superficial gangrene</li>
                            <li><strong>renal:</strong> oliguria, azotemia, cortical necrosis</li>
                            <li><strong>pulmonary:</strong> ARDS</li>
                            <li><strong>GI:</strong> acute ulceration</li>
                            <li><strong>RBC:</strong> microangiopathic hemolysis</li>
                        </ul>
                        <h5>Signs of Hemorrhagic Diathesis (Late DIC)</h5>
                        <ul>
                             <li><strong>neurologic:</strong> intracranial bleeding</li>
                            <li><strong>skin:</strong> petechiae, eccyhmosis, oozing from puncture sites</li>
                            <li><strong>renal:</strong> hematuria</li>
                            <li><strong>mucosal:</strong> gingival oozing, epistaxis, massive bleeding</li>
                        </ul>
                         <h5>Diagnosis</h5>
                        <ul>
                            <li>clinical picture</li>
                            <li><strong>laboratory</strong>
                                <ul>
                                    <li>primary hemostasis: decreased platelets</li>
                                    <li>secondary hemostasis: prolonged INR (PT), PTT, TT, decreased fibrinogen and other factors</li>
                                    <li>fibrinolysis increased FDPs, short lysis time</li>
                                    <li>extent of fibrin deposition: urine output, urea, RBC fragmentation</li>
                                </ul>
                            </li>
                        </ul>
                        <h5>Management</h5>
                        <ul>
                            <li>recognize early</li>
                            <li>TREAT UNDERLYING DISORDER</li>
                            <li>life support measures, O2, blood transfusion, fluid therapy</li>
                            <li>replacement of hemostatic elements with platelet transfusion, FFP, cryoprecipitate</li>
                        </ul>
                    </div>
                </section>
                <!-- END: secondary-hemostasis-disorders -->

                <!-- START: thrombosis -->
                <section id="thrombosis" class="content-section" aria-labelledby="section-heading-6">
                    <h2 id="section-heading-6" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">THROMBOSIS</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Virchow's Triad</h3>
                        <ul>
                            <li>stasis</li>
                            <li>hypercoaguable state</li>
                            <li>endothelial injury</li>
                        </ul>
                        <h3 class="subsection-heading">Etiology</h3>
                        <ul>
                            <li>endothelial damage</li>
                            <li><strong>blood flow</strong>
                                <ul>
                                    <li>stasis</li>
                                    <li>turbulence</li>
                                    <li>hyperviscosity</li>
                                </ul>
                            </li>
                            <li><strong>blood components</strong>
                                <ul>
                                    <li>platelets</li>
                                    <li>contact factors</li>
                                    <li>thrombin</li>
                                    <li>Factor VIII</li>
                                    <li>fibrin</li>
                                </ul>
                            </li>
                            <li><strong>hypercoagulable state due to</strong>
                                <ul>
                                    <li>cancer</li>
                                    <li>pregnancy</li>
                                    <li>birth control pills</li>
                                    <li>DIC</li>
                                    <li>lipids</li>
                                    <li>decreased physiological inhibitors (antithrombin-III, protein C , protein S )</li>
                                    <li>hereditary resistance to activated protein C (Factor V Leiden mutation)</li>
                                    <li>prothrombin variant 20210A</li>
                                    <li>nephrotic syndrome</li>
                                </ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading">Management (acute and prophylaxis)</h3>
                        <ul>
                            <li>hyperhomocysteine</li>
                            <li><strong>anticoagulants</strong>
                                <ul>
                                    <li>low molecular weight heparin
                                        <ul>
                                            <li>no test required</li>
                                            <li>reduced incidence of HIT</li>
                                        </ul>
                                    </li>
                                    <li>unfractionated heparin
                                        <ul><li>maintain PTT 1.5-2.5 x the normal control</li></ul>
                                    </li>
                                    <li>coumadin (see Table 11)</li>
                                    <li>hirudin</li>
                                </ul>
                            </li>
                            <li><strong>thrombolytics</strong>
                                <ul>
                                    <li>snake venom enzymes (ancrod)</li>
                                    <li>plasminogen activators (streptokinase, urokinase, tPA)</li>
                                </ul>
                            </li>
                            <li><strong>antiplatelet agents</strong>
                                <ul>
                                    <li>ASA</li>
                                    <li>sulfinopyrazone</li>
                                    <li>dipyridamole</li>
                                </ul>
                            </li>
                        </ul>
                        <div class="table-container">
                             <table class="content-table">
                                <caption>Table 11. Monitoring Coumadin (Warfarin) Therapy (therapeutic ranges)</caption>
                                <thead>
                                    <tr><th rowspan="2"></th><th colspan="2">INR</th></tr>
                                    <tr><th>Range</th><th>Target</th></tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>- pre-operative<br>- surgery<br>- hip surgery</td>
                                        <td>1.5-2.5<br>2-3</td>
                                        <td>2<br>2.5</td>
                                    </tr>
                                    <tr>
                                        <td>- prevention of venous thrombosis</td>
                                        <td>2-3</td>
                                        <td>2.5</td>
                                    </tr>
                                    <tr>
                                        <td>- active venous thrombosis, pulmonary embolism and prevention of recurrent venous thrombosis</td>
                                        <td>2-4</td>
                                        <td>3</td>
                                    </tr>
                                    <tr>
                                        <td>- prevention of arterial thrombo-embolism including mechanical heart valves</td>
                                        <td>3-4.5</td>
                                        <td>3.5</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: thrombosis -->
                
                <!-- START: hit -->
                <section id="hit" class="content-section" aria-labelledby="section-heading-7">
                    <h2 id="section-heading-7" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">HIT-I</h3>
                        <ul>
                            <li>non-immune</li>
                            <li>decrease in platelet count usually seen early (48-72 hours post administration) but may take up to 1 week to appear</li>
                            <li>transient thrombocytopenia, returns to normal once heparin discontinued</li>
                            <li>no intravascular thrombosis</li>
                            <li>likely due to platelet aggregation and sequestration</li>
                        </ul>
                        <h3 class="subsection-heading">HIT-II</h3>
                        <ul>
                            <li>immune-mediated</li>
                            <li>typically occurs at day 5-15 of heparin therapy and decline is gradual</li>
                            <li>HIT can begin sooner in patients who have received heparin in the past three months</li>
                            <li>delayed-onset HIT occurs several days after discontinuing heparin</li>
                            <li>typical platelet count in patients with HIT ranges from 25 to 100 x 10<sup>9</sup>/L</li>
                        </ul>
                        <h3 class="subsection-heading">Pathogenesis</h3>
                        <ul>
                            <li>immunoglobulin-mediated adverse drug reaction</li>
                            <li>pathogenic antibody, usually IgG recognizes a multimolecular complex of heparin and platelet factor 4, resulting in platelet activation via platelet Fc receptors and activation of the coagulation system</li>
                        </ul>
                        <h3 class="subsection-heading">Clinical Complications</h3>
                        <ul>
                            <li>cases of serious bleeding related to thrombocytopenia have been reported
                                <ul>
                                    <li>intravascular thrombosis
                                        <ul><li>both venous (DVT, PE, venous gangrene) and arterial thrombi (MI, stroke, limb vessels) can form</li></ul>
                                    </li>
                                </ul>
                            </li>
                            <li>heparin-induced skin necrosis</li>
                            <li>unusual thrombotic complications include mesenteric artery or vein occlusion, adrenal hemorrhage and infarction</li>
                            <li>acute platelet activation syndromes
                                <ul><li>acute inflammatory reactions (eg. fever/chills, flushing, etc.), transient global amnesia</li></ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading">Laboratory Tests</h3>
                        <ul>
                            <li>C-serotonin release assay</li>
                            <li>ELISA
                                <ul><li>measures binding of antibody in patients serum to PF4:heparin complex</li></ul>
                            </li>
                        </ul>
                        <h3 class="subsection-heading">Management</h3>
                        <ul>
                            <li>discontinuation of heparin</li>
                            <li>platelet count should return to normal in a few days</li>
                            <li>danaparoid (organon) is the preferred agent if anti-thrombic therapy is indicated</li>
                            <li>low-molecular-weight heparin is less likely to cause HIT in de novo use but still carries an increased risk if previously sensitized with unfractionated heparin</li>
                            <li>other alternatives include ancrod and hirudin</li>
                            <li>patient may be re-exposed to heparin only under careful supervision</li>
                        </ul>
                    </div>
                </section>
                <!-- END: hit -->

            </main>

            <!-- Bottom Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hematology-hemoglobinopathies-aplastic-anemia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 50%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 3 of 6</span> <!-- Update text -->
                    </div>
                    <a href="hematology-myeloid-malignancies.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>